Enanta Pharmaceuticals (STU:9EP) EBIT: €-44.26 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
58 GF Score
Price €11.50
GF Value €7.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals EBIT?

Enanta Pharmaceuticals STU:9EP 58 EBIT is €-44.26 Mil as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Enanta Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-8.45 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-44.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Enanta Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -28.26%. Enanta Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -55.83%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Enanta Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.17%.

Enanta Pharmaceuticals  (STU:9EP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Enanta Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-41.008 * ( 1 - 0% )/( (141.839 + 148.358)/ 2 )
=-41.008/145.0985
=-28.26 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=281.396 - 8.079 - ( 158.715 - max(0, 38.198 - 169.676+158.715))
=141.839

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=272.219 - 9.707 - ( 141.665 - max(0, 40.172 - 154.326+141.665))
=148.358

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Enanta Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-33.796/( ( (60.9 + max(-24.43, 0)) + (60.161 + max(-24.275, 0)) )/ 2 )
=-33.796/( ( 60.9 + 60.161 )/ 2 )
=-33.796/60.5305
=-55.83 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.253 + 0 + 3.708) - (8.079 + 0 + 27.312)
=-24.43

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.755 + 0 + 5.89) - (9.707 + 0 + 27.213)
=-24.275

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Enanta Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-44.261/243.650
=-18.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals EBIT Related Terms

Enanta Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals EBIT Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -91.44 -123.41 -117.92 -96.27 -64.64

Enanta Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.57 -14.40 -13.87 -7.54 -8.45

STU:9EP vs PBYI, IPSC, BNTC: EBIT Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enanta Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's EV-to-EBIT falls into.


STU:9EP
58GF Score
Enanta Pharmaceuticals Inc STU:9EP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-44.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-44.26 Mil mean?
Enanta Pharmaceuticals (STU:9EP) has a EBIT of €-44.26 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Enanta Pharmaceuticals.
Is Enanta Pharmaceuticals' EBIT too high?
Enanta Pharmaceuticals' current EBIT is €-44.26 Mil. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' EBIT compare to PBYI and IPSC?
Enanta Pharmaceuticals' EBIT of €-44.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Enanta Pharmaceuticals. Enanta Pharmaceuticals's current EBIT is €-44.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.57, compared to a current price of €11.50 — trading 51.9% above its estimated fair value. The current EBIT is €-44.26 Mil. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current EBIT is €-44.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.50 is trading 51.9% above its estimated GF Value™ of €7.57. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • EBIT: €-44.26 Mil
  • GF Value™: €7.57 vs. price of €11.50 (51.9% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score

Get the complete analysis for STU:9EP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.50
Price
€7.57
GF Value